Back to Search
Start Over
A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma
- Source :
- Blood; December 2015, Vol. 126 Issue: 23 p1492-1492, 1p
- Publication Year :
- 2015
-
Abstract
- Flinn: Celgene Corporation: Research Funding. Boccia:Incyte Corporation: Honoraria. Berdeja:Array: Research Funding; Curis: Research Funding; Onyx: Research Funding; Abbvie: Research Funding; Acetylon: Research Funding; Novartis: Research Funding; Celgene: Research Funding; Janssen: Research Funding; BMS: Research Funding; MEI: Research Funding; Takeda: Research Funding.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 126
- Issue :
- 23
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs53082543
- Full Text :
- https://doi.org/10.1182/blood.V126.23.1492.1492